Form 4 for NVCR NovoCure Ltd

Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001562180-24-001982 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2024-02-29	2023-12-31+	NVCR	Ben Arye Barak	GC	A - Grant	$16.29	+81.9K	35.3K	New	+$1.33M
D	2024-02-29	2024-02-27	NVCR	Ben Arye Barak	GC	A - Grant	$16.30	+125.1K	125.1K	New	+$2.04M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2024-02-27	A	A	81,799	$16.30	117,122	D	—	—	(F3) Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
2	Common	Ordinary Shares	2023-12-31	A	A	128	$12.69	35,323	D	—	—	(F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c). (F2) In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.
3	Derivative	Stock Options (Right to buy)	2024-02-27	A	A	125,078	$16.30	125,078	D	$16.30 · 2025-02-27 to 2034-02-26	125,078 Ordinary Shares	(F4) Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.